Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
/in Dendritic Cells, International Publications, NSCLC /von 2019-06-21 / J. Cell. Physiol. 2019 Jun;Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-06-19 / Oncology 2019 Jun;:1-14Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von 2019-06-17 / J Clin Oncol 37, 2019 (suppl; abstr e13526)Phase I/II Pilot Study of Wilms‘ Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
/in Dendritic Cells, International Publications /von 2019-06-06 / Ther Apher Dial 2019 Jun;23(3):279-288Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-04 / J Clin Oncol 37, 2019 (suppl; abstr e21025)Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-04 / J Clin Oncol 37, 2019 (suppl; abstr e21024)A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.
/in Dendritic Cells, NSCLC /von 2019-06-02 / J Clin Oncol 37, 2019 (suppl; abstr 9039)Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
/in Dendritic Cells, Urothelial Carcinoma /von 2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de